On Sept. 5, 2025, the U.S. Food and Drug Administration (FDA) approved Inlexzo (gemcitabine intravesical system) for adults ...

Stage 0 cancer, known as carcinoma in situ, marks the earliest stage of cancer development. Abnormal cells are present but ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients ...

Stage 0 cancer, or carcinoma in situ, represents the earliest detectable phase where abnormal cells are confined to their ...

Urothelial cancers that are either non-invasive papillary (Ta), carcinoma in situ (CIS) flat tumors, or invade the subepithelial connective tissue (T1) are collectively termed non-muscle-invasive ...

Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...

TAR-200, a gemcitabine-releasing system, received FDA priority review for high-risk non-muscle invasive bladder cancer unresponsive to BCG. Phase 2b SunRISe-1 trial data showed an 82.4% complete ...

ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, helping eliminate cancer Already approved in the ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its marketing authorization applications (MAA) for ANKTIVA® (nogapendekin ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun ...